Anika Therapeutics (ANIK) Receivables - Net (2016 - 2025)
Anika Therapeutics (ANIK) has disclosed Receivables - Net for 16 consecutive years, with $24.8 million as the latest value for Q4 2025.
- Quarterly Receivables - Net rose 5.18% to $24.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $24.8 million through Dec 2025, up 5.18% year-over-year, with the annual reading at $24.8 million for FY2025, 5.18% up from the prior year.
- Receivables - Net for Q4 2025 was $24.8 million at Anika Therapeutics, up from $22.2 million in the prior quarter.
- The five-year high for Receivables - Net was $38.4 million in Q2 2023, with the low at $22.2 million in Q3 2025.
- Average Receivables - Net over 5 years is $29.6 million, with a median of $29.4 million recorded in 2021.
- The sharpest move saw Receivables - Net soared 40.61% in 2021, then crashed 32.7% in 2025.
- Over 5 years, Receivables - Net stood at $31.3 million in 2021, then rose by 10.68% to $34.6 million in 2022, then fell by 21.95% to $27.0 million in 2023, then decreased by 12.7% to $23.6 million in 2024, then increased by 5.18% to $24.8 million in 2025.
- According to Business Quant data, Receivables - Net over the past three periods came in at $24.8 million, $22.2 million, and $24.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.